Last updated: February 15, 2026
What is the current market status of drug NDC 00480-3156?
The drug identified by NDC 00480-3156 is Apalutamide, marketed as Erleada by Janssen Pharmaceuticals. Approved in 2018 by the FDA, it is indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). As of 2023, Erleada maintains a significant market presence in prostate cancer treatment, driven by its indication expansion and the growing prostate cancer patient pool.
What are the sales figures and market penetration trends?
- U.S. Sales: Estimated at approximately $350 million for 2022, a 15% increase year-over-year, according to IQVIA reports.
- Market Share: Erleada accounts for roughly 25% of the prostate cancer drug market, trailing behind Zytiga (abiraterone) and Xtandi (enzalutamide).
- Pricing Strategy: Listed at $32,000 per year per patient, with typical net prices around $22,000 after discounts and rebates.
Current market penetration is influenced by:
- Expansion of approved indications.
- Competition from similar androgen receptor inhibitors.
- Prescriber familiarity.
What factors influence future price projections?
- Patent Landscape and Patent Expirations: Patents protecting Erleada are expected to expire in 2035. Patent cliffs tend to accelerate generic entry, decreasing prices.
- Regulatory Approvals: Expanding indications, such as potential approvals for earlier prostate cancer stages, can sustain or grow sales, supporting higher pricing in the short term.
- Competitive Dynamics: Generics could emerge as early as 2035, depending on patent litigation and biosimilar regulations.
- Pricing Trends in Oncology: Oncology drugs continue to see high launch prices, but market pressure from biosimilars and value-based pricing is increasing.
- Reimbursement Policies: CMS and private insurers' reimbursement policies impact net prices and patient access.
How do prices of similar drugs compare?
| Drug |
Year Approved |
Indication |
Approximate Price (per year) |
Market Share (2022) |
| Erleada (Apalutamide) |
2018 |
nmCRPC, mHSPC |
$32,000 |
25% |
| Zytiga (Abiraterone) |
2011 |
Metastatic prostate cancer |
$34,000 |
30% |
| Xtandi (Enzalutamide) |
2012 |
Various prostate cancer stages |
$35,000 |
35% |
Prices reflect list prices; effective net prices are often lower, adjusted for rebates and discounts.
What are the price projection scenarios?
| Scenario |
Assumptions |
Price Range (per year) |
Timeline |
| Conservative (A) |
Patent protection holds, no major competition |
$30,000 to $33,000 |
2023–2028 |
| Moderate (B) |
Early generic entry predicted given patent expiration in 2035 |
$20,000 to $25,000 |
2028–2035 |
| Aggressive (C) |
Faster generic competition due to litigation, biosimilars |
$10,000 to $15,000 |
2032–2035 |
Current forecasts favor scenario A until patent expiry, with prices declining substantially with generic market entry.
What are the key market and pricing risks?
- Patent challenges or invalidations could accelerate generic entry.
- Regulatory decisions expanding indications might temporarily boost prices.
- Insurance reimbursement policies could shift, impacting net pricing.
- Competitive drug launches may erode market share.
What are the implications for stakeholders?
- Investors: Expect stable pricing until 2035, followed by significant declines.
- Pharmaceutical companies: Focus on patent enforcement, indication expansion, and pipeline diversification.
- Payors: Monitor for cost-containment strategies, especially as generics become available.
Closing summary
Market growth for Erleada is driven by expanding indications and increasing prostate cancer prevalence. Pricing remains high until patent expiration, with projections indicating a decline post-2035 following generic entry. Competition and regulatory changes will influence the future pricing landscape.
Key Takeaways
- Current U.S. sales approximate $350 million, with steady growth.
- Pricing at around $32,000 annually is typical, with margins dependent on rebates.
- Patent expiry forecasted in 2035, after which prices are expected to decline sharply.
- Competitive landscape includes Zytiga and Xtandi, with biosimilar options influencing future prices.
- Monitoring regulatory and legal developments is critical to projecting long-term price trends.
FAQs
-
When will generic versions of Apalutamide likely enter the market?
Patent expiration is expected in 2035, after which generics may enter depending on patent challenges and regulatory decisions.
-
Can the price of Erleada decrease before patent expiry?
Yes. Market dynamics, competition, or negotiated discounts could lower effective prices pre-expiry.
-
How does the competition compare in efficacy?
All three leading drugs—Erleada, Zytiga, Xtandi—show similar efficacy in prostate cancer; selection often depends on tolerability, patient profile, and pricing.
-
Are there any ongoing indications that could extend patent protection?
No current indications are patent-protected beyond initial approval; future approvals for broader or new indications could influence market exclusivity.
-
What are the potential impacts of upcoming regulatory policies?
Policies favoring biosimilars, price negotiation, or value-based pricing could accelerate price declines and market shifts.
Sources:
[1] IQVIA. "Pharmaceutical Market Reports 2022."
[2] FDA. "Approved Drug Products: Erleada," 2018.
[3] Statista. "Prostate Cancer Market Analysis 2022."
